Almac Announces Launch of IXRS®3 Partnership Network
April 25, 2023
Almac Clinical Technologies, a member of the Almac Group, has announced the launch of its IXRS®3 Partnership Network for biopharmaceutical sponsors, which aims to accelerate the development and delivery of innovative eClinical solutions.
Almac Clinical Technologies has over 25 years’ experience of working in partnership with specialist technology and service companies and understands that the interoperability of eClinical data systems is a priority for biopharmaceutical sponsors.
This Partnership Network gives sponsors and CROs the opportunity to share data and solutions to build a more inclusive clinical trial experience for all sites and patients.
George Tiger, Global Vice President of Almac Clinical Technologies Global Business Development, said: “Managing a mix of technologies throughout the course of a clinical trial is a common pain point for sponsors and service providers. Clinical technology companies who can demonstrate flexibility and interoperability can make the study build process and support more seamless, more transparent, and more cost-effective for sponsors and sites.
“IXRS®3 is the most trusted Interactive Response Technology platform in the industry1 and our aim is to build the most in-depth and innovative partnership network in the eClinical space.
“We are thrilled that some of the most innovative names in the industry have already joined the Partnership Network including Veeva, THREAD, Kayentis, N-SIDE, and ESMS Global. Their expertise spans clinical development cloud software, eCOA, decentralised clinical trials, clinical supply planning and optimisation, and medical monitoring.”
Mike Hutton, the Head of Partnerships and Strategic Alliances at ACT concluded: “We share an important goal with our trusted partners to provide our sponsors, sites, and patients with the best eClinical technology and services in the industry, and we can do it much better together.
“We look forward to growing this network with more partners as we strive to improve interoperability, making clinical trials easier to conduct for our sites and sponsors and participation easier for patients.“ For more information and to join the IXRS®3 Partnership Network, click here.
ENDS
About Almac Clinical Technologies
Almac Clinical Technologies is a global provider of Interactive Response Technology (IRT) and expert consultancy for the biopharmaceutical industry, empowering trial sponsors to pro-actively manage sites, patients, and clinical supplies through our industry-leading technology solutions.
Our solutions facilitate more than simplifying patient and trial material management – they engineer quality into the clinical trial process. We provide sponsors and CROs with the visibility and control needed to make data-driven decisions by leveraging advanced supply management functionality, coupled with real-time site and patient data in a closed-loop environment.
For more information, visit: almacgroup.com/clinical-technologies
About Almac Group
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 6,500 highly skilled personnel across 18 facilities including Europe, the US and Asia.
1 Independent Blinded Market Research Survey of 7 IRT providers January/February 2022 with Almac being compared against 6 other companies.
Media Contact:
Julie Watts
Almac Group
Share